Caribou Biosciences, Inc

Caribou Biosciences, Inc., based in Berkeley, CA, is a clinical-stage biopharmaceutical company dedicated to developing innovative genome-edited allogeneic cell therapies aimed at treating severe human diseases. Utilizing next-generation CRISPR genome-editing technology, the company focuses on creating off-the-shelf CAR-T cell therapies to enable rapid and broad patient access in the fight against hematologic malignancies.

Caribou is recognized as a leader in the CRISPR field, employing its proprietary chRDNA technology to enhance the efficacy of its cell therapies through strategies such as checkpoint disruption and immune cloaking. With a commitment to advancing transformative medical treatments, the company aims to significantly improve patient outcomes in challenging health conditions.

Generated from the website